Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tagraxofusp by Stemline Therapeutics for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase III for Chronic Myelomonocytic Leukemia (CMML). According to...
Tagraxofusp by Stemline Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
Tagraxofusp by Stemline Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Tagraxofusp by Stemline Therapeutics for Myelofibrosis: Likelihood of Approval
Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II...
Tagraxofusp by Stemline Therapeutics for Systemic Mastocytosis: Likelihood of Approval
Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Systemic Mastocytosis. According to GlobalData, Phase...
Tagraxofusp by Stemline Therapeutics for Hypereosinophilic Syndrome: Likelihood of Approval
Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Hypereosinophilic Syndrome. According to GlobalData, Phase...
Tagraxofusp by Stemline Therapeutics for Myelofibrosis: Likelihood of Approval
Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II...
Tagraxofusp by Stemline Therapeutics for Systemic Mastocytosis: Likelihood of Approval
Tagraxofusp is under clinical development by Stemline Therapeutics and currently in Phase II for Systemic Mastocytosis. According to GlobalData, Phase...
Izorlisib by Stemline Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Izorlisib is under clinical development by Stemline Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
MEN-1703 by Stemline Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
MEN-1703 is under clinical development by Stemline Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
MEN-1703 by Stemline Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
MEN-1703 is under clinical development by Stemline Therapeutics and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Felezonexor by Stemline Therapeutics for Gastrointestinal Tumor: Likelihood of Approval
Felezonexor is under clinical development by Stemline Therapeutics and currently in Phase I for Gastrointestinal Tumor. According to GlobalData, Phase...
Felezonexor by Stemline Therapeutics for Neuroendocrine Tumors: Likelihood of Approval
Felezonexor is under clinical development by Stemline Therapeutics and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase...
Felezonexor by Stemline Therapeutics for Urinary Tract Cancer: Likelihood of Approval
Felezonexor is under clinical development by Stemline Therapeutics and currently in Phase I for Urinary Tract Cancer. According to GlobalData,...
Felezonexor by Stemline Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Felezonexor is under clinical development by Stemline Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
Felezonexor by Stemline Therapeutics for Solid Tumor: Likelihood of Approval
Felezonexor is under clinical development by Stemline Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Felezonexor by Stemline Therapeutics for Colorectal Cancer: Likelihood of Approval
Felezonexor is under clinical development by Stemline Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
Felezonexor by Stemline Therapeutics for Breast Cancer: Likelihood of Approval
Felezonexor is under clinical development by Stemline Therapeutics and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
MEN-1703 by Stemline Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval
MEN-1703 is under clinical development by Stemline Therapeutics and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Izorlisib by Stemline Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
Izorlisib is under clinical development by Stemline Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...